Healthcare
Live Price
Offline$12.64
-1.10% today
1Y Change
+41.38%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xencor, Inc. (XNCR) is a Healthcare stock with a market cap of $980.00M and listed on NASDAQ. The stock last traded around $12.64 and up 41.4% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of +13.7%, EPS growth of +65.4%, a dividend yield of 0.0%. What stands out right now is revenue +13.7%, EPS +65.4%, free cash flow +33.6% with operating margin -141.4% and ROIC -21.5%. Valuation sits in the middle of the pack at price/sales 7.8. Stock Foundry combines XNCR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XNCR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XNCR Max Drawdown
-42.61%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XNCR and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$275.1M
+67.2% YoY
FY Net Income
$82.6M
+249.7% YoY
Free Cash Flow
-$32.8M
-73.6% YoY
Revenue Growth
+13.7%
EPS Growth
+65.4%
Gross Margin
93.7%
Net Margin
-73.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 126M | 110M | 175M | 165M | 275M |
| Gross Profit | 115M | 110M | 175M | 165M | 275M |
| Operating Income | -178M | -178M | -132M | -82M | 44M |
| EBITDA | -47M | -186M | -102M | -46M | 90M |
| Net Income | -92M | -233M | -133M | -55M | 83M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 54M | 41M | 54M | 54M | 143M |
| Total Assets | 875M | 952M | 953M | 846M | 838M |
| Total Liabilities | 240M | 278M | 284M | 119M | 105M |
| Shareholder Equity | 636M | 678M | 669M | 727M | 734M |
| Total Debt | 188M | 232M | 83M | 60M | 34M |
| Net Debt | 134M | 191M | 30M | 6M | -110M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
17M
-168.8% YoY
Capital Expenditures
16M
+63.2% YoY
Free Cash Flow
33M
-73.6% YoY
Key ratios
Gross Margin
93.7%
Operating Margin
-141.4%
Net Margin
-73.2%
ROE
-14.6%
Debt / Equity
0.30x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.